-transparent.png){kind=logo}
3'-Azido-3'-deoxythymidine (AZT) is one of the primary chemotherapeutic agents used in the treatment of human immunodeficiency virus (HIV) infection. Unfortunately, AZT therapy is accompanied by severe side effects. Using Golgi-enriched membrane fractions, we have determined that 3'-azido-3'-deoxythymidine monophosphate, the primary AZT metabolite in treated cells, potently inhibits protein glycosylation. This inhibition results from direct competition with several pyrimidine-sugars for transport into Golgi membranes. This potential mechanism of cytotoxicity does not involve 3'-azido-3'-deoxythymidine triphosphate, the AZT metabolite most likely responsible for its antiviral effects; thus, it may be possible to develop novel therapeutic strategies that prevent inhibition of glycosylation without affecting the anti-HIV properties of AZT.
E T Hall, and
J P Yan, and
P Melançon, and
R D Kuchta
April 2006,
Biochemical pharmacology,
E T Hall, and
J P Yan, and
P Melançon, and
R D Kuchta
April 1988,
Acta crystallographica. Section C, Crystal structure communications,
E T Hall, and
J P Yan, and
P Melançon, and
R D Kuchta
May 1994,
European journal of haematology,
E T Hall, and
J P Yan, and
P Melançon, and
R D Kuchta
July 1988,
British journal of haematology,
E T Hall, and
J P Yan, and
P Melançon, and
R D Kuchta
February 1990,
AIDS research and human retroviruses,
E T Hall, and
J P Yan, and
P Melançon, and
R D Kuchta
April 1993,
Antimicrobial agents and chemotherapy,
E T Hall, and
J P Yan, and
P Melançon, and
R D Kuchta
January 1989,
Drug metabolism and disposition: the biological fate of chemicals,
E T Hall, and
J P Yan, and
P Melançon, and
R D Kuchta
May 1996,
Journal of immunoassay,
E T Hall, and
J P Yan, and
P Melançon, and
R D Kuchta
June 1994,
The Journal of biological chemistry,
E T Hall, and
J P Yan, and
P Melançon, and
R D Kuchta
March 2000,
The Journal of biological chemistry,
